ReviewVaccines2017
Harnessing Nanoparticles for Immunomodulation and Vaccines.
Review in Vaccines, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
80 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Vaccines for the common cold.The Cochrane database of systematic reviews · 2022Pooled it
- Trial
- Induction of neutralising antibodies against conserved rhinovirus capsid protein VP4 is dependent on presentation of VP4 peptide immunogens in a virus-like conformation.PLoS pathogens · 2026Article
- Recent advances in HIV-1 envelope-based vaccine designs for guiding broadly neutralizing antibody response.Journal of virology · 2026Review
- Application and Research Progress of Self-Assembling Protein Nanoparticles in Vaccine Development.International journal of molecular sciences · 2026Review
- Trace Elements and Viral Infectious Diseases: Dual Roles in Pathogenesis and Immunity.Infectious disease reports · 2026Review
- EPIclip: A Novel Approach for the Production of Decorated Virus-Like Particles Mediated by High-Affinity Protein Binding Partners.Vaccines · 2026Article
- Creating unimolecular multivalent diversity in protein conjugates via the Passerini multicomponent bioconjugation with isocyanoproteins.Communications chemistry · 2026Article
- Intelligence Disclosure on Deploying SpyTag/SpyCatcher for Nanoparticle Assembly.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Hantavirus GnACS infectious diseases · 2025Article
- Nanoparticle vaccine based on the pre-fusion F glycoprotein of respiratory syncytial virus elicits robust protective immune responses.Journal of virology · 2025Article
- Synthesis of Chirally Chimeric Protein Nanoparticle Vaccines via Mirror-Image Spy Chemistry.Angewandte Chemie (International ed. in English) · 2025Article
- A novel nanoparticle vaccine displaying multistage tuberculosis antigens confers protection in mice infected with H37Rv.NPJ vaccines · 2025Article
- Nanoimmunotherapy: the smart trooper for cancer therapy.Exploration of targeted anti-tumor therapy · 2025Review
- A miniature low-immunogenic platform for the biosynthesis of self-assembling protein nanoparticles.Nanotheranostics · 2025Article
- Modulation of allergic airways disease employing bio-mimetic nanoparticles with TLR agonists.Frontiers in allergy · 2025Article
- Combined TLR2/TLR4 activation equip non-mucosal dendritic cells to prime Th1 cells with gut tropism.iScience · 2024Article
- Article
- Self-assembling nanoparticle engineered from the ferritinophagy complex as a rabies virus vaccine candidate.Nature communications · 2024Article
- In vitro cytotoxicity evaluation of green synthesized alumina nanoscales on different mammalian cell lines.Scientific reports · 2024Article
20 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The first successful use of nanoparticles (NPs) for vaccination was reported almost 40 years ago with a virus-like particle-based vaccine against Hepatitis B. Since then, the term NP has been expanded to accommodate a large number of novel nano-sized particles engineered from a range of materials. The great interest in NPs is likely not only a result of the two successful vaccines against hepatitis B and Human Papilloma Virus (HPV) that use this technology, but also due to the versatility of those small-sized particles, as indicated by the wide range of applications reported so far, ranging from medicinal and cosmetics to purely technical applications. In this review, we will focus on the use of NPs, especially virus-like particles (VLPs), in the field of vaccines and will discuss their employment as vaccines, antigen display platforms, adjuvants and drug delivery systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.